April 2003 New Products

Unit-dose of ointments new to market

Healthpoint, Ltd. (Fort Worth, Tex.) introduced the first unit-dose packaging of prescription ointments Panafil® and Accuzyme® in barcoded 6-g units to complement the standard 30-g tubes. Accuzyme is an enzymatic debriding ointment used to treat necrotic wounds, pressure ulcers, and burns by removing dead tissue without harming living tissue. Panafil is a healing, debriding, and deodorizing ointment that also controls local inflammation. The unit doses are available as of February 1 to distributor/drug wholesalers in the United States.

For more information, visit www.healthpoint.com.- OWM

New topical skin adhesive available

Ethicon products (Somerville, NJ) announced that the Food and Drug Administration (FDA) has approved a new, thicker formula of Dermabond Topical Skin Adhesive (2-octyl cyanoacrylate). The new formulation, High Viscosity Dermabond Topical Skin Adhesive, offers better application control, especially important on certain areas of the body such as around the eyes and nose.

The product is a liquid skin adhesive only intended for topical application to hold closed easily approximated skin edges of wounds from surgical incisions, including punctures from minimally invasive surgery and simple, thoroughly cleansed, trauma-induced lacerations. It may be used in conjunction with, but not in place of, deep dermal stitches.

Research studies have concluded that wounds and incisions treated with the adhesive lead to excellent cosmetic results, similar to those with suturing, and provide patients with a fast and relatively painless closure. Studies also show that patients receiving the adhesive were less likely to require anesthesia, did not require the physicians to wait for the onset of anesthesia, and had faster wound closure times.

The product is contraindicated for use on any wounds with evidence of active infection, gangrene, or decubitus etiology. It should not be used on mucosal surfaces or across mucocutaneous junctions (eg, lips, oral cavity), or on skin that is regularly exposed to body fluids or with dense natural hair (eg, scalp). Patients with a known hypersensitivity to cyanoacrylate or formaldehyde should not be treated with the product. It also should not be applied to the eye or used in high skin tension areas or across areas of increased skin tension, such as knuckles, elbows, or knees, unless the joint will be immobilized during the skin healing period.

Visit www.dermabondtraining.com for more information.- OWM

New antifungal barrier cream for skin protection incontinence

Swiss-American Products, Inc. (Dallas, Tex.) announces the availability of Elta Trivase, a new antifungal barrier cream used to protect skin against urinary and fecal incontinence episodes.

The product uses a triple action approach to form a waterproof barrier against moisture; therefore, eliminating the need to apply other barrier creams to keep the antifungal in place. The active ingredient, 2% miconazole nitrate, helps prevent and treat fungal infections including Candida. Zinc oxide, petrolatum, and dimethicone contribute to a long-lasting waterproof barrier. The third component is a proprietary vegetable enzyme blend that helps remodel the epidermal layer, soothe skin, and minimize irritation. This approach promotes the maintenance of healthy skin

The product is applied with minimal drag and adheres to previously wet and moist areas. Any standard cleanser can be used for product removal.

For more information, visit the website at www.elta.net or call 800-633-8872.- OWM

Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
  • Use to create page breaks.

More information about formatting options

Enter the characters shown in the image.